Skip to main content
Tulane Home Tulane Home

Prostate Clinical Trials

BRAVE PDL-1
PDL-1 Inhibition With Avelumab and Concurrent Second-Generation ADT in African Americans With Castrate-Resistant Metastatic Prostate Cancer
More Information

Constellation CPI 1205
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer
More Information

NiraRad
A Phase 1B Trial of Radium-223 and Niraparib in Patients With Castration Resistant Prostate Cancer (NiraRad)
More Information

BAY 16996
A Phase 4 Long-Term Follow-Up Study to Define the Safety Profile of Radium-223 Dichloride
More Information

NRG GU002
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
More Information

TUHC 07/25/13 - Genetics of Prostate Cancer

IRONMAN
Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)
More Information

PANTHER
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer (PANTHER)
More Information

AAA
Phase 1/2 Open-Label, Multi-Center, Dose-Escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-Ligand Therapy in Patients with Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-Resistant Prostate Cancer, Following Previous Systemic Treatment
More Information

Merck 010
A Phase 3, Randomized Open-Label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-Generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)
More Information

Merck 641
A Phase 3, Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
More Information

ARROW        
A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prOstate cancer (mCRPC) patients Who are 18F-DCFPyL prostate-specific membrane antigen (PSMA)-avid, chemotherapy-naïve, and progressed on abiraterone
More Information

BED IIT-382    
Changes in 18F-fluciclovine Positron Emission Tomography (PET) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate: A Pilot Study
More Information

C17-191         
A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castration Sensitive Prostate Cancer with and without DNA Repair Mutations. (CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone.)
More Information